High concentrations of serum Lp(a) are associated with accelerated progression of low-attenuation plaque (necrotic core) in patients with advanced multivessel coronary artery disease despite receiving guideline-based preventative therapies. The gene discussed is LPA; the disease is coronary artery disorder.